CT and PET-CT Surveillance in Stages 3A to 3D Melanoma Results in More False-Positive than True-Positive Findings and Should Not be Routinely Recommended-Reference-Cited by-同舟云学术

CT and PET-CT Surveillance in Stages 3A to 3D Melanoma Results in More False-Positive than True-Positive Findings and Should Not be Routinely Recommended

Published:2021-03-18 Issue:S3 Volume:28 Page:817-818
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Taylor Nicholas A.^ORCID,Brodland David G.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-09820-3.pdf

Reference6 articles.

1. Turner RM, Dieng M, Khanna N, et al. Performance of long-term CT and PET/CT surveillance for detection of distant recurrence in patients with resected stage IIIA–D melanoma. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09270-3.

2. Mettler FA, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248:254–63. https://doi.org/10.1148/radiol.2481071451.

3. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–9. https://doi.org/10.1002/cncr.21189.

4. Bikchandani J, Wood J, Richards AT, Smith RB. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma. Head Neck. 2014;36:1313–6. https://doi.org/10.1002/hed.23456.

5. Ravichandran S, Nath N, Jones DC, et al. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. SurgOncol. 2020;35:533–9. https://doi.org/10.1016/j.suronc.2020.10.018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al.;Annals of Surgical Oncology;2021-05-02